Skip to content
OpenCapital
Get started

Anika Therapeutics ANIK Q2 2025 earnings

Reported July 30, 2025 · Before market open

Revenue$28.2MBeat by $685.7K
EPS-$0.13In line
Revenue estimate$27.5M
EPS estimate-$0.13

Next report

Jul 29, 2026 (Today)
Revenue estimate$29.2M
EPS estimate$0.03
View report

Financials

Q2 2025

Income statement

See full
Revenue$28.2M-32.7%
Net income-$4.0M-4,411%

Balance sheet

See full
Cash & equivalents$53.2M-15.4%
Total debt$25.0M-11.0%
Total equity$147.7M-29.8%
Total assets$187.7M-28.5%

Cash flow

See full
Operating cash flow-$189.0K+82.3%
CapEx$1.5M-56.9%
Free cash flow-$1.7M+63.0%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$161.05M-56.4%
Enterprise value$132.88M-60.3%
P/S1.7×-0.5×

Profitability

See full
Net margin-65.1%+56.4pp

Returns & leverage

See full
Return on equity-33.9%+4.0pp
Debt / equity0.2×0.0×
Current ratio6.2×+0.2×

Segments

By geography

See full
Other Location$5.5M+12.6%
Europe$4.8M-16.8%

By product

See full
OEM Channel$16.3M—
Commercial Channel$11.9M—

Versus estimates

Revenue

Q1 2026$29.6MBeat by $1.5MQ4 2025$30.6MBeat by $1.7MQ3 2025$27.8MBeat by $17.0K
Q2 2025$28.2MBeat by $685.7K
Q1 2025$26.2MMiss by $1.9MQ4 2024-$1.3MMiss by $29.4M

Diluted EPS

Q1 2026$0.27Beat by $0.34Q4 2025$0.31Beat by $0.44Q3 2025$0.04Beat by $0.02
Q2 2025-$0.13In line
Q1 2025-$0.06Miss by $0.15Q4 2024-$0.03Miss by $0.02

Ask the moment Anika Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Anika Therapeutics report Q2 2025 earnings?
Anika Therapeutics (ANIK) reported Q2 2025 earnings on July 30, 2025 before market open.
What were Anika Therapeutics's Q2 2025 revenue and EPS?
Anika Therapeutics reported revenue of $28.2M and eps of $-0.13 for Q2 2025.
Did Anika Therapeutics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $27.5M by $685.7K. EPS beat the consensus estimate of $-0.13 by $0.00.
How did Anika Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 32.7% from $41.9M a year earlier.
Where can I find Anika Therapeutics's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001171843-25-004826) directly on SEC EDGAR. The filing index links above go to sec.gov.